(NASDAQ: PACB) Pacific Biosciences Of California's forecast annual revenue growth rate of 12.78% is forecast to beat the US Medical Devices industry's average forecast revenue growth rate of 7.85%, and while it is not forecast to beat the US market's average forecast revenue growth rate of 26.17%.
Pacific Biosciences Of California's revenue in 2025 is $156,110,000.On average, 13 Wall Street analysts forecast PACB's revenue for 2025 to be $49,062,535,601, with the lowest PACB revenue forecast at $46,332,166,747, and the highest PACB revenue forecast at $51,093,040,931. On average, 13 Wall Street analysts forecast PACB's revenue for 2026 to be $56,496,708,223, with the lowest PACB revenue forecast at $50,630,470,190, and the highest PACB revenue forecast at $63,582,450,936.
In 2027, PACB is forecast to generate $68,054,969,334 in revenue, with the lowest revenue forecast at $55,400,355,493 and the highest revenue forecast at $80,961,894,489.